@article{A.2019, author = "Hiraoka A. and Kumada T. and Atsukawa M. and Hirooka M. and Tsuji K. and Ishikawa T. and Takaguchi K. and Kariyama K. and Itobayashi E. and Tajiri K. and Shimada N. and Shibata H. and Ochi H. and Tada T. and Toyoda H. and Nouso K. and Tsutsui A. and Nagano T. and Itokawa N. and Hayama K. and Imai M. and Joko K. and Tanaka H. and Tamai T. and Koizumi Y. and Hiasa Y. and Michitaka K. and Kudo M. and Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)", title = "{Supplementary Material for: Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma}", year = "2019", month = "7", url = "https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Important_Clinical_Factors_in_Sequential_Therapy_Including_Lenvatinib_against_Unresectable_Hepatocellular_Carcinoma/8869625", doi = "10.6084/m9.figshare.8869625.v1" }